Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients - PubMed (original) (raw)
Case Reports
Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients
Kirsten A Petrie et al. PLoS One. 2009.
Abstract
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, heritable condition typified by progression of extensive ossification within skeletal muscle, ligament and tendon together with defects in skeletal development. The condition is easily diagnosed by the presence of shortened great toes and there is severe advancement of disability with age. FOP has been shown to result from a point mutation (c.617G>A) in the ACVR1 gene in almost all patients reported. Very recently two other mutations have been described in three FOP patients. We present here evidence for two further unique mutations (c.605G>T and c.983G>A) in this gene in two FOP patients with some atypical digit abnormalities and other clinical features. The observation of disparate missense mutations mapped to the GS and kinase domains of the protein supports the disease model of mild kinase activation and provides a potential rationale for phenotypic variation.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
Similar articles
- Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, Delai P, Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G, Hoover-Fong J, Köster B, Pauli RM, Reardon W, Zaidi SA, Zasloff M, Morhart R, Mundlos S, Groppe J, Shore EM. Kaplan FS, et al. Hum Mutat. 2009 Mar;30(3):379-90. doi: 10.1002/humu.20868. Hum Mutat. 2009. PMID: 19085907 Free PMC article. - Mutational screening of ACVR1 gene in Brazilian fibrodysplasia ossificans progressiva patients.
Carvalho DR, Navarro MM, Martins BJ, Coelho KE, Mello WD, Takata RI, Speck-Martins CE. Carvalho DR, et al. Clin Genet. 2010 Feb;77(2):171-6. doi: 10.1111/j.1399-0004.2009.01256.x. Epub 2009 Oct 1. Clin Genet. 2010. PMID: 19796185 - The ACVR1 617G>A mutation is also recurrent in three Japanese patients with fibrodysplasia ossificans progressiva.
Nakajima M, Haga N, Takikawa K, Manabe N, Nishimura G, Ikegawa S. Nakajima M, et al. J Hum Genet. 2007;52(5):473-475. doi: 10.1007/s10038-007-0128-3. Epub 2007 Mar 10. J Hum Genet. 2007. PMID: 17351709 - ACVR1 (587T>C) mutation in a variant form of fibrodysplasia ossificans progressiva: second report.
Nakahara Y, Katagiri T, Ogata N, Haga N. Nakahara Y, et al. Am J Med Genet A. 2014 Jan;164A(1):220-4. doi: 10.1002/ajmg.a.36219. Epub 2013 Nov 20. Am J Med Genet A. 2014. PMID: 24259422 Review. - Challenges in the diagnosis of fibrodysplasia ossificans progressiva with the ACVR1 mutation (c.774G > C, p.R258S): a case report and review of literature.
Yang S, Cui R, Li J, Dai R. Yang S, et al. Orphanet J Rare Dis. 2024 Sep 30;19(1):360. doi: 10.1186/s13023-024-03363-y. Orphanet J Rare Dis. 2024. PMID: 39350127 Free PMC article. Review.
Cited by
- The biological function of type I receptors of bone morphogenetic protein in bone.
Lin S, Svoboda KK, Feng JQ, Jiang X. Lin S, et al. Bone Res. 2016 Apr 5;4:16005. doi: 10.1038/boneres.2016.5. eCollection 2016. Bone Res. 2016. PMID: 27088043 Free PMC article. Review. - The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
Alessi Wolken DM, Idone V, Hatsell SJ, Yu PB, Economides AN. Alessi Wolken DM, et al. Bone. 2018 Apr;109:210-217. doi: 10.1016/j.bone.2017.06.011. Epub 2017 Jun 16. Bone. 2018. PMID: 28629737 Free PMC article. Review. - Identification and characterization of regulatory elements in the promoter of ACVR1, the gene mutated in Fibrodysplasia Ossificans Progressiva.
Giacopelli F, Cappato S, Tonachini L, Mura M, Di Lascio S, Fornasari D, Ravazzolo R, Bocciardi R. Giacopelli F, et al. Orphanet J Rare Dis. 2013 Sep 18;8:145. doi: 10.1186/1750-1172-8-145. Orphanet J Rare Dis. 2013. PMID: 24047559 Free PMC article. - Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Mohedas AH, Wang Y, Sanvitale CE, Canning P, Choi S, Xing X, Bullock AN, Cuny GD, Yu PB. Mohedas AH, et al. J Med Chem. 2014 Oct 9;57(19):7900-15. doi: 10.1021/jm501177w. Epub 2014 Sep 4. J Med Chem. 2014. PMID: 25101911 Free PMC article. - Sporadic Fibrodysplasia Ossificans Progressiva in an Egyptian Infant with c.617G > A Mutation in ACVR1 Gene: A Case Report and Review of Literature.
Al-Haggar M, Ahmad N, Yahia S, Shams A, Hasaneen B, Hassan Hassan R, Wahba Y, Salem NA, Abdel-Hady D. Al-Haggar M, et al. Case Rep Genet. 2013;2013:834605. doi: 10.1155/2013/834605. Epub 2013 Jan 23. Case Rep Genet. 2013. PMID: 23424689 Free PMC article.
References
- Shore EM, Feldman GJ, Xu M, Kaplan FS. The genetics of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab. 2005;3:201–204.
- Connor JM, Smith R. The cervical spine in fibrodysplasia ossificans progressiva. Br J Radiol. 1982;55:492–496. - PubMed
- Smith R. 49th ENMC-Sponsored International Workshop: fibrodysplasia (myositis) ossificans progressiva (FOP). 14–16 February 1997, Naarden, The Netherlands. Neuromuscul Disord. 1997;7:407–410. - PubMed
- Hebela N, Shore EM, Kaplan FS. Three pairs of monozygotic twins with fibrodysplasia ossificans progressiva: the role of environment in the progression of heterotopic ossification. Clin Rev Bone Miner Metab. 2005;3:205–208.
- Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38:525–527. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases